Lates News

According to the AI flash news of eacheconomicnews, Open Source Securities released a research report on August 28th, giving Kangyuan Pharmaceuticals (600557.SH) a buy rating. The main reasons for the rating include: 1) revenue growth of tablet, patch, and gel products, while sales of other product categories are relatively under pressure; 2) innovation leading development, deepening layout in the biopharmaceutical and chemical drug sectors. (Daily Economic News)